Keyword: Voyager Therapeutics
Steven Paul, M.D., left Eli Lilly after 17 years to “do something a bit more entrepreneurial." He went on to work on CNS disorders in small biotechs.
Two years after it walked away from a Voyager Therapeutics-partnered Parkinson’s gene therapy, Sanofi Genzyme is at it again.
Boston startup Karuna Therapeutics has raised a chunky $68 million as it looks to beef up work on its Alzheimer’s/schizophrenia combo therapy.
Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.
The deal sees Neurocrine commit to $1.7 billion in milestones in return for Parkinson’s disease program VY-AADC and other assets.
CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.
Roche's Omar Khwaja, M.D., Ph.D., will become chief medical officer at gene therapy specialist Voyager Therapeutics.
Four months after Voyager's chief and founder said he would step down, the neurological disease biotech has found a new leader.
AbbVie has teamed with Voyager Therapeutics on a tau protein-targeting program, paying $69 million for an option on the Alzheimer’s disease candidate.
Bob Hugin retires from Celgene, Voyager founder steps down as CEO, Boehringer named new U.S. chief to replace retiring Fonteyne.